- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Key Metrics
- Market Cap (In Cr) 22641.57
- Beta 0.86
- Div. Yield (%) 0.09
- P/B 6.89
- TTM P/E 52.94
- Peg Ratio 9.25
- Sector P/E 55.93
- D/E -
- Open Price 568.05
- Prev Close 567.35
Analysis
-
1 Week0.05%
-
3 Months-8.81%
-
6 Month0.63%
-
YTD-3.22%
-
1 Year-1.88%
- 22% Low risk
- 22% Moderate risk
- 22% Balanced Risk
- 22% High risk
- 22% Extreme risk
8 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
- Ratings
- Current
- Strong Sell
- 0
- Sell
- 0
- Hold
- 1
- Buy
- 3
- Strong Buy
- 4
Syngene International News
Biocon divests over ₹1,220 crore stake in Syngene International in bulk deal
2 min read . 06 Sep 2022Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 2604.2
- Selling/ General/ Admin Expenses Total
- 1037.3
- Depreciation/ Amortization
- 305.2
- Other Operating Expenses Total
- 11.8
- Total Operating Expense
- 2203.3
- Operating Income
- 400.9
- Net Income Before Taxes
- 484.4
- Net Income
- 395.8
- Diluted Normalized EPS
- 10.45
- Period
- 2022
- Total Assets
- 5563.8
- Total Liabilities
- 2266.2
- Total Equity
- 3297.6
- Tangible Book Valueper Share Common Eq
- 81.96
- Period
- 2022
- Cashfrom Operating Activities
- 580.6
- Cashfrom Investing Activities
- -611.5
- Cashfrom Financing Activities
- -31.3
- Net Changein Cash
- -61.5
- Period
- 2021
- Total Revenue
- 2184.3
- Selling/ General/ Admin Expenses Total
- 933.4
- Depreciation/ Amortization
- 270.3
- Other Operating Expenses Total
- 12.3
- Total Operating Expense
- 1769.1
- Operating Income
- 415.2
- Net Income Before Taxes
- 469.2
- Net Income
- 404.9
- Diluted Normalized EPS
- 9.35
- Period
- 2021
- Total Assets
- 4883.2
- Total Liabilities
- 2061.8
- Total Equity
- 2821.4
- Tangible Book Valueper Share Common Eq
- 70.06
- Period
- 2021
- Cashfrom Operating Activities
- 701.2
- Cashfrom Investing Activities
- -628.1
- Cashfrom Financing Activities
- 58
- Net Changein Cash
- 130.3
- Period
- 2020
- Total Revenue
- 2011.9
- Selling/ General/ Admin Expenses Total
- 835.2
- Depreciation/ Amortization
- 215.3
- Other Operating Expenses Total
- 8
- Total Operating Expense
- 1627.7
- Operating Income
- 384.2
- Net Income Before Taxes
- 516.9
- Net Income
- 412.1
- Diluted Normalized EPS
- 8.92
- Period
- 2020
- Total Assets
- 4162.9
- Total Liabilities
- 1987.1
- Total Equity
- 2175.8
- Tangible Book Valueper Share Common Eq
- 54.35
- Period
- 2020
- Cashfrom Operating Activities
- 677.1
- Cashfrom Investing Activities
- -428.4
- Cashfrom Financing Activities
- -225.5
- Net Changein Cash
- 27.8
- Period
- 2019
- Total Revenue
- 1825.6
- Selling/ General/ Admin Expenses Total
- 709.7
- Depreciation/ Amortization
- 160.3
- Other Operating Expenses Total
- 4.6
- Total Operating Expense
- 1451.1
- Operating Income
- 374.5
- Net Income Before Taxes
- 415.4
- Net Income
- 331.6
- Diluted Normalized EPS
- 8.36
- Period
- 2019
- Total Assets
- 3703.5
- Total Liabilities
- 1735.1
- Total Equity
- 1968.4
- Tangible Book Valueper Share Common Eq
- 49.36
- Period
- 2019
- Cashfrom Operating Activities
- 630.4
- Cashfrom Investing Activities
- -646.5
- Cashfrom Financing Activities
- -72.4
- Net Changein Cash
- -87.5
- Period
- 2018
- Total Revenue
- 1423.1
- Selling/ General/ Admin Expenses Total
- 600.5
- Depreciation/ Amortization
- 131.4
- Other Operating Expenses Total
- 6.3
- Total Operating Expense
- 1154.6
- Operating Income
- 268.5
- Net Income Before Taxes
- 372.5
- Net Income
- 305.4
- Diluted Normalized EPS
- 7.87
- Period
- 2018
- Total Assets
- 3189
- Total Liabilities
- 1468.6
- Total Equity
- 1720.4
- Tangible Book Valueper Share Common Eq
- 43.21
- Period
- 2018
- Cashfrom Operating Activities
- 446.2
- Cashfrom Investing Activities
- -349.3
- Cashfrom Financing Activities
- -78.7
- Net Changein Cash
- 18.2
- Period
- 2017
- Total Revenue
- 1200.9
- Selling/ General/ Admin Expenses Total
- 445
- Depreciation/ Amortization
- 114.3
- Other Operating Expenses Total
- 19
- Total Operating Expense
- 930.5
- Operating Income
- 270.4
- Net Income Before Taxes
- 346.5
- Net Income
- 287.3
- Diluted Normalized EPS
- 7.28
- Period
- 2017
- Total Assets
- 2774.8
- Total Liabilities
- 1361.7
- Total Equity
- 1413.1
- Tangible Book Valueper Share Common Eq
- 34.93
- Period
- 2017
- Cashfrom Operating Activities
- 397.7
- Cashfrom Investing Activities
- -469.1
- Cashfrom Financing Activities
- -80.8
- Net Changein Cash
- -152.8
- Period
- 2022-12-31
- Total Revenue
- 785.9
- Selling/ General/ Admin Expenses Total
- 210.8
- Depreciation/ Amortization
- 94.6
- Other Operating Expenses Total
- 122.3
- Total Operating Expense
- 633.9
- Operating Income
- 152
- Net Income Before Taxes
- 139.9
- Net Income
- 109.7
- Diluted Normalized EPS
- 2.71
- Period
- 2022-12-31
- Period
- 2022-12-31
- Period
- 2022-09-30
- Total Revenue
- 768.1
- Selling/ General/ Admin Expenses Total
- 207.2
- Depreciation/ Amortization
- 90.2
- Other Operating Expenses Total
- 126.8
- Total Operating Expense
- 623.2
- Operating Income
- 144.9
- Net Income Before Taxes
- 130
- Net Income
- 102
- Diluted Normalized EPS
- 2.53
- Period
- 2022-09-30
- Total Assets
- 5381.1
- Total Liabilities
- 2107.2
- Total Equity
- 3273.9
- Tangible Book Valueper Share Common Eq
- 81.67
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 70.1
- Cashfrom Investing Activities
- -18.2
- Cashfrom Financing Activities
- -166
- Net Changein Cash
- -102.6
- Period
- 2022-06-30
- Total Revenue
- 644.5
- Selling/ General/ Admin Expenses Total
- 186.1
- Depreciation/ Amortization
- 86.1
- Other Operating Expenses Total
- 121
- Total Operating Expense
- 554.4
- Operating Income
- 90.1
- Net Income Before Taxes
- 92.8
- Net Income
- 73.9
- Diluted Normalized EPS
- 1.85
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 758.1
- Selling/ General/ Admin Expenses Total
- 173.6
- Depreciation/ Amortization
- 80.3
- Other Operating Expenses Total
- 128.5
- Total Operating Expense
- 597.2
- Operating Income
- 160.9
- Net Income Before Taxes
- 179.1
- Net Income
- 147.8
- Diluted Normalized EPS
- 3.81
- Period
- 2022-03-31
- Total Assets
- 5563.8
- Total Liabilities
- 2266.2
- Total Equity
- 3297.6
- Tangible Book Valueper Share Common Eq
- 81.96
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 580.6
- Cashfrom Investing Activities
- -611.5
- Cashfrom Financing Activities
- -31.3
- Net Changein Cash
- -61.5
- Period
- 2021-12-31
- Total Revenue
- 641.4
- Selling/ General/ Admin Expenses Total
- 188.8
- Depreciation/ Amortization
- 78.5
- Other Operating Expenses Total
- 97
- Total Operating Expense
- 536.4
- Operating Income
- 105
- Net Income Before Taxes
- 128.4
- Net Income
- 104
- Diluted Normalized EPS
- 2.55
- Period
- 2021-12-31
- Period
- 2021-12-31
Forecast
Forecast
Forecast
Technical
- 5 Day565.65
- 10 Day575.59
- 20 Day591.99
- 50 Day589.31
- 100 Day587.05
- 300 Day581.43
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Lupin
- 744.55
- 5.05
- 0.68
- 922.5
- 583.05
- 33633.49
- Biocon
- 241.15
- 7.75
- 3.32
- 410.5
- 229.7
- 27841.53
- Syngene International
- 560
- -7.35
- -1.3
- 681.64
- 507.65
- 22641.57
- IPCA Laboratories
- 853.65
- -1.85
- -0.22
- 1089
- 830
- 21712.01
- Glaxosmithkline Pharmaceutical
- 1235.05
- -9.95
- -0.8
- 1667.53
- 1230.7
- 21092.75
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Lupin
- 140.44
- 2.77
- 0.08
- 0.13
- Biocon
- 39.09
- 3.32
- 10.68
- 12.71
- Syngene International
- 54.25
- 6.89
- 16.75
- 18.41
- IPCA Laboratories
- 24.31
- 3.95
- 18.3
- 14.45
- Glaxosmithkline Pharmaceutical
- 56.25
- 7.92
- 16.01
- 10.19
Shareholding
- Category
- Percentage
- No. of shares
- Public Shareholding
- 34.67%
- 139,169,608
- GOVERNMENT PENSION FUND GLOBAL
- 1.21%
- 4,861,314
- Others
- 15.21%
- 61,047,845
- Others
- 6.82%
- 27,391,318
- ICICI PRUDENTIAL MIDCAP FUND
- 1.28%
- 5,130,691
- UTI-UNIT LINKED INSURANCE PLAN
- 1.26%
- 5,070,655
- MIRAE ASSET HEALTHCARE FUND
- 1.26%
- 5,057,380
- Others
- 1.21%
- 4,849,660
- Others
- 1.75%
- 7,006,499
- Others
- 1.7%
- 6,820,188
- Others
- 1.07%
- 4,313,334
- Others
- 0.55%
- 2,195,691
- Others
- 0.43%
- 1,723,379
- HUF
- 0.25%
- 1,021,965
- Clearing Members
- 0.04%
- 163,637
- Independent Directors
- 0.02%
- 100,000
- Trusts
- 0%
- 9,769
- Others
- 0.32%
- 1,266,948
- Others
- 0.22%
- 902,827
- Others
- 0.03%
- 109,939
- FOREIGN INSTITUTIONAL INVESTORS
- 0.02%
- 67,000
- Others
- 0.01%
- 55,350
- Others
- 0%
- 4,000
- Others
- 0%
- 219
- Non Promoter - Non Public shareholder
- 0.47%
- 1,900,827
- Others
- 0.47%
- 1,900,827
- Promoter & Promoter Group Shareholding
- 64.86%
- 260,364,065
- BIOCON LIMITED
- 64.56%
- 259,185,608
- BIOCON LIMITED EMPLOYEE WELFARE TRUST (MURALI KRISHNAN K N and AMITAVA SAHA)
- 0.28%
- 1,134,001
- KIRAN MAZUMDAR SHAW
- 0.01%
- 21,964
- RAVI RASENDRA MAZUMDAR
- 0%
- 8,806
- DEV MAZUMDAR
- 0%
- 13,686
Shareholding Pattern
Shareholding Trend
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 23-Jan-23
- Quarterly Results
- 19-Oct-22
- Quarterly Results
- 20-Jul-22
- Quarterly Results
- 27-Apr-22
- Audited Results & Final Dividend
- 19-Jan-22
- Quarterly Results
- 20-Oct-21
- Quarterly Results
- 20-Jul-21
- Quarterly Results
- 27-Apr-21
- Audited Results & Final Dividend
- 20-Jan-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 20-Jul-22
- 28-Apr-22
- AGM
- 01-Jun-22
- 02-May-22
- POM
- 01-Mar-22
- 28-Jan-22
- POM
- 21-Jul-21
- 28-Apr-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 28-Apr-22
- 01-Jul-22
- 30-Jun-22
- 0.5
- 27-Apr-22
- 01-Jul-22
- 30-Jun-22
- 0.5
Company Profile
ABOUT Syngene International
- Industry Biotechnology & Drugs
- ISIN INE398R01022
- BSE Code 539268
- NSE Code SYNGENE
Syngene International Limited is an India-based contract research company. The Company is engaged in providing services from early discovery and development to commercial manufacturing for small and large molecules. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation and analytical development along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects, which is designed to provide a range of advance programs through target validation, translational interrogation, therapeutic discovery and preclinical development for both large and small molecules, as well as specialty modalities, such as targeted protein degradation. It serves clients ranging from multinational corporations to start-ups.
MANAGEMENT
- Jonathan Hunt Chief Executive Officer, Managing Director, Executive Director, Member of the Executive Committee
- Sibaji Biswas Chief Financial Officer, Member of the Executive Committee
- Mahesh Bhalgat Chief Operating Officer, Member of the Executive Committee
- Kenneth Barr Senior Vice President - Discovery Services, Member of the Executive Committee
- Alex Del Priore Senior Vice President - Manufacturing Services, Member of the Executive Committee
- Jan-Olav Henck Senior Vice President - Development Services, Member of the Executive Committee
- Priyadarshini Mahapatra Compliance Officer, Company Secretary
- Alok Mehrotra Chief Quality Officer, Member of the Executive Committee
- Ashu Tandon Chief Commercial Officer, Member of the Executive Committee
Company Summary
SYNGENE INTERNATIONAL SUMMARY
Syngene International is trading 1.30% lower at Rs 560.00 as compared to its last closing price. Syngene International has been trading in the price range of 568.5 & 555.8. Syngene International has given -3.22% in this year & 0.05% in the last 5 days.
Syngene International has TTM P/E ratio 52.94 as compared to the sector P/E of 55.93. There are 8 analysts who have initiated coverage on Syngene International. There are 4 analysts who have given it a strong buy rating & 3 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.
The company posted a net profit of 109.7 Crores in its last quarter.
Listed peers of Syngene International include Lupin (0.68%), Biocon (3.32%), Syngene International (-1.3%) etc.
Syngene International has a 64.86% promoter holding & 0.47% public holding.
FAQs about Syngene International
- 0 analysts have given a strong sell rating
- 0 analysts have given a sell rating
- 1 analysts have given a hold rating
- 3 analysts have given a buy rating
- 4 analysts have given a strong buy rating
- TTM P/E: 52.94
- Sector P/E: 55.93
- Dividend Yield: 0.09%
- D/E ratio: -